Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 20/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29709949 | 1.00 | ELANE (1.00) | ELANECYP3A4CYP2C9 | |
| SCHEMBL3663656 | 1.00 | ELANE (1.00) | ELANECYP3A4CYP2C9 | |
| SCHEMBL29443698 | 1.00 | ELANE (1.00) | ELANECYP3A4CYP2C9 | |
| SCHEMBL29636980 | 1.00 | ELANE (1.00) | ELANECYP3A4CYP2C9 | |
| SCHEMBL121431 | 1.00 | ELANE (1.00) | ELANECYP3A4CYP2C9 | |
| SCHEMBL586622 | 0.93 | ELANE (1.00) | ELANECYP3A4CYP2C9 | |
| SCHEMBL15866526 | 0.93 | ELANE (1.00) | ELANECYP3A4CYP2C9 | |
| SCHEMBL3723159 | 0.93 | ELANE (0.87) | ELANECYP3A4CYP2C9 | |
| SCHEMBL2117084 | 0.93 | ELANE (1.00) | ELANECYP3A4CYP2C9 | |
| SCHEMBL122824 | 0.93 | ELANE (0.87) | ELANECYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260130899-A1 | METHOD OF TREATMENT FOR PREVENTION OF GLUCOCORTICOID TOXICITY AND/OR ENHANCEMENT OF MUSCLE REGENERATION VIA NEUTROPHIL ELASTASE INHIBITION | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2026-05-14 | — | — | US | claimed |
| EP-4585223-A2 | TRANSPLANTED CELL PROTECTION VIA INHIBITION OF POLYMORPHONUCLEAR CELLS | The Regents of the University of California (US) | 2025-07-16 | — | — | EP | claimed |
| US-20250064792-A1 | MUSCLE REGENERATION | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2025-02-27 | — | — | US | claimed |
| US-20240216353-A1 | METHOD OF TREATMENT FOR PREVENTION OF GLUCOCORTICOID TOXICITY AND/OR ENHANCEMENT OF MUSCLE REGENERATION VIA NEUTROPHIL ELASTASE INHIBITION | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2024-07-04 | — | — | US | claimed |
| US-20230127290-A1 | MUSCLE REGENERATION | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2023-04-27 | — | — | US | claimed |
| US-20230058557-A1 | TRANSPLANTED CELL PROTECTION VIA INHIBITION OF POLYMORPHONUCLEAR CELLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-02-23 | — | — | US | claimed |
| EP-4090349-A2 | TRANSPLANTED CELL PROTECTION VIA INHIBITION OF POLYMORPHONUCLEAR CELLS | The Regents of The University of California (US) | 2022-11-23 | — | — | EP | claimed |
| US-20260130899-A1 | METHOD OF TREATMENT FOR PREVENTION OF GLUCOCORTICOID TOXICITY AND/OR ENHANCEMENT OF MUSCLE REGENERATION VIA NEUTROPHIL ELASTASE INHIBITION | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2026-05-14 | — | — | US | disclosed |
| US-12415819-B2 | Cu- and Ni-catalyzed decarboxylative borylation reactions | THE SCRIPPS RESEARCH INSTITUTE (US) | 2025-09-16 | — | — | US | disclosed |
| EP-4585223-A2 | TRANSPLANTED CELL PROTECTION VIA INHIBITION OF POLYMORPHONUCLEAR CELLS | The Regents of the University of California (US) | 2025-07-16 | — | — | EP | disclosed |
| WO-2025056012-A1 | NEUTROPHIL ELASTASE INHIBITOR AND USE THEREOF | 上海壹迪生物技术有限公司 | 2025-03-20 | — | — | WO | disclosed |
| CN-119638624-A | Neutrophil elastase inhibitor and application thereof | 上海壹迪生物技术有限公司 | 2025-03-18 | — | — | CN | disclosed |
| US-20250064792-A1 | MUSCLE REGENERATION | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2025-02-27 | — | — | US | disclosed |
| US-20220354833-A1 | ALVELESTAT FOR USE IN THE TREATMENT OF GRAFT REJECTION, BRONCHIOLITIS OBLITERANS SYNDROME AND GRAFT VERSUS HOST DISEASE | MEREO BIOPHARMA 4 LIMITED (GB) | 2022-11-10 | — | — | US | disclosed |
| US-20220296597-A1 | USE OF A NEUTROPHIL ELASTASE INHIBITOR IN LUNG DISEASE | PH PHARMA CO., LTD. (KR) | 2022-09-22 | — | — | US | disclosed |
| CN-114761015-A | Use of inhibitors of neutrophil elastase in pulmonary diseases | PH制药有限公司 | 2022-07-15 | — | — | CN | disclosed |
| EP-4017497-A1 | USE OF A NEUTROPHIL ELASTASE INHIBITOR IN LUNG DISEASE | pH Pharma Co., Ltd. (KR) | 2022-06-29 | — | — | EP | disclosed |
| CN-114650819-A | Avermectistat for treating graft rejection, bronchiolitis obliterans syndrome and graft-versus-host disease | 美莱奥生物制药第四有限公司 | 2022-06-21 | — | — | CN | disclosed |
| WO-2022040246-A1 | IMMUNE MODULATION OF MYELOID DERIVED SUPPRESSIVE CELL FUNCTION FOR CANCER TREATMENT | STIMIT CORPORATION (US) | 2022-02-24 | — | — | WO | disclosed |
| US-20220024949-A1 | CU-AND NI-CATALYZED DECARBOXYLATIVE BORYLATION REACTIONS | THE SCRIPPS RESEARCH INSTITUTE | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260130899-A1 | METHOD OF TREATMENT FOR PREVENTION OF GLUCOCORTICOID TOXICITY AND/OR ENHANCEMENT OF MUSCLE REGENERATION VIA NEUTROPHIL ELASTASE INHIBITION | SERPINB1, ELANE, CELA1 | ELANE 2/4885CYP3A4 1289/4885CYP2C9 2062/4885 |
| US-20220296597-A1 | USE OF A NEUTROPHIL ELASTASE INHIBITOR IN LUNG DISEASE | SERPINB1, ELANE, SERPINA2 | ELANE 2/4885CYP3A4 4041/4885CYP2C9 3753/4885 |
| US-12415819-B2 | Cu- and Ni-catalyzed decarboxylative borylation reactions | PCSK9, PCSK7, PCSK6 | ELANE 530/4885CYP3A4 1080/4885CYP2C9 333/4885 |
| US-20220024949-A1 | CU-AND NI-CATALYZED DECARBOXYLATIVE BORYLATION REACTIONS | PCSK9, PCSK7, PCSK6 | ELANE 530/4885CYP3A4 1080/4885CYP2C9 333/4885 |
| US-20220354833-A1 | ALVELESTAT FOR USE IN THE TREATMENT OF GRAFT REJECTION, BRONCHIOLITIS OBLITERANS SYNDROME AND GRAFT VERSUS HOST DISEASE | SERPINB1, ELANE, SERPINE1 | ELANE 2/4885CYP3A4 3120/4885CYP2C9 2908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.